Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Anti-amyloid drugs

Eli Lilly HQ

Lilly adds to data backing breast cancer candidate abemaciclib

US pharma giant’s drug achieves PFS rate of 16.4 months

- PMLiVE

Lilly pitches Cyramza at bladder cancer

Pharma firm is now armed with phase III data from its RANGE study

- PMLiVE

Eli Lilly appoints senior VP for corporate affairs and communications

Leigh Ann Pusey joins from the American Insurance Association

Roche Basel Switzerland

Tecentriq bladder cancer approval in doubt after trial failure

The PD-L1 inhibitor failed to extend overall survival in a phase III study

Eli Lilly HQ

Surging Trulicity takes sting out of Lilly’s arthritis setback

First quarter sales of the diabetes treatment were up by 160%, exceeding analysts predictions

Roche Basel Switzerland

Roche claims another FDA green light for Tecentriq

Wins approval for the treatment's first-line use in bladder cancer

Eli Lilly HQ

FDA turns down Lilly and Incyte JAK inhibitor after delay

Analysts suggest safety issues in high doses

Roche Basel Switzerland

Roche’s Alecensa beats Xalkori as first-line lung cancer therapy

Data shows ALK inhibitor reduces risk of disease worsening

Roche Basel Switzerland

Roche sets disruptive price for new MS drug Ocrevus in US

Firm will significantly under cut rivals like Merck's Rebif

- PMLiVE

Mylan deal with Roche clears path to biosimilar Herceptin launch

Covers global markets with the exception of Japan, Brazil and Mexico

Deal Watch February 2017

Actelion, Johnson & Johnson, Sanofi, Takeda and more feature in this month's pharma deals round-up

- PMLiVE

AZ gets US approval for diabetes combo Qtern

Wins licensing for Onglyza/Farxiga dual-therapy after rejection by the FDA in 2015

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links